

March 6, 2014



AntriaBio, Inc. to Present at 26th Annual ROTH Conference

MENLO PARK, CA -- (Marketwired) -- 03/06/14 -- [AntriaBio, Inc.](#) (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that Nevan Elam, Chairman and Chief Executive Officer is scheduled to present at the 26th Annual ROTH Conference. The conference is taking place March 9-12, 2014, at The Ritz-Carlton, Laguna Niguel, in Dana Point, CA.

Mr. Elam will provide an overview of the Company's business during his presentation on Monday, March 10, 2014 at 5:30 p.m. PT and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

The live presentation will be webcast and will remain available for 90 days following the presentation. To access the webcast, please visit <http://wsw.com/webcast/roth28/antb>.

About AntriaBio, Inc.

AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes.

For more information visit: www.antriabio.com.

Forward-Looking Statements

This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances

that occur after the date on which such statements were made.

AntriaBio, Inc. Contact:

Jenene Thomas

Jenene Thomas Communications, LLC

(908) 938-1475

[Email Contact](#)

Source: AntriaBio, Inc.